Psychological trauma and depression in recovered COVID-19 patients: a telecommunication ba

Amit Srivastava from Pfizer conducted a cross-sectional telemedicine study from November to December 2020. The dataset contains survey responses from 503 recovered COVID-19 patients, assessing PTSD symptoms and depression using the NSESSS and PHQ-9 scales. Prevalence rates of PTSD symptoms and depression were 56.9% and 29% respectively, with higher odds for patients who had severe disease or required oxygen support.

Use Cases

• Analyzing the association between COVID-19 disease severity and PTSD symptoms based on odds ratios reported in the description
• Modeling risk factors for depression in post-COVID populations based on patient characteristics like age and oxygen support requirements
• Comparing psychological outcomes between asymptomatic and symptomatic recovered patients based on the reported prevalence rates

Strengths

• Includes data from 503 recovered COVID-19 patients with a mean age of 41.90 years
• Reports specific prevalence rates: 56.9% for PTSD symptoms and 29% for depression
• Provides concrete statistical measures, such as odds ratios comparing mild versus severe disease forms

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Last update date is unknown; freshness unverified

Provenance

Source

Amit Srivastava, Pfizer (United States)

Collection Method

Cross-sectional study using a telemedicine model to enroll patients from a database provided by health authorities.

Time Range

November 9, 2020 to December 23, 2020